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Abundant biologically active peptides have been discovered from frog skin secretions, a rich natural source of bioactive compounds
with great potential in drug discovery. In this study, three Caeridin peptides, namely, Caeridin-1, S5-Caeridin-1, and Caeridin-a1,
were discovered from the skin secretion of the Australian White’s tree frog, Litoria caerulea, for the ﬁrst time, by means of
combining transcriptomic and peptidomic analyses. It also represents the ﬁrst report on bioactive Caeridins since this family of
peptides was initially studied 20 years ago. Chemically synthetic versions of each natural Caeridin demonstrated promising
bioactivities either on rat smooth muscles or against microbial growth. Speciﬁcally, Caeridin-1 produced contraction of rat
bladder smooth muscle, while S5-Caeridin-1 induced relaxation of rat ileum smooth muscle, both at nanomolar concentrations.
Moreover, Caeridin-a1 was shown to potently inhibit the growth of the planktonic Gram-positive bacteria Staphylococcus aureus
(S. aureus), methicillin-resistant S. aureus (MRSA), and Enterococcus faecalis (E. faecalis), the Gram-negative bacterium,
Escherichia coli (E. coli), and the yeast, Candida albicans (C. albicans). The discovery of these Caeridins may induce further
intensive and systematic studies of frog skin peptides to promote the discovery of natural templates as lead compounds for drug
discovery and therapeutic application.
1. Introduction
In recent years, peptide and peptide-based drugs have been
developing fast and have pioneered an essential area in the
pharmaceutical industry [1]. Peptide-based medicinal ther-
apy could oﬀer beneﬁts over other biologics, while demand-
ing less costs in production [1]. Recent trends suggest that
the application of therapeutic peptides is becoming more
popular, and it has extended to the treatment of many dis-
eases, such as infection, cancer, enzyme deﬁciency disorders,
protein-dysfunction disorders, and even genetic and degen-
erative diseases [2].
Frog skin with poisonous glands can produce secretions
in a holocrinemanner and release complex chemical contents
[3–5]. On the one hand, peptides and proteins contained in
these secretions have been considered to play diﬀerent but
important roles in regulating frogs’ physiological functions
and defense against predators and microorganisms. On the
other hand, they have been proven to hold hidden treasures
to supplement drug development [6]. However, with the
observed global decline in the frog population during the
1980s, including species extinction, it became apparent that
this potentially valuable natural resource needed environ-
mental protection and animal conservation to ensure peptide
discovery and acquisition from these natural products could
continue and play a role in the future development of novel
therapeutic peptides [7, 8].
The Australian White’s tree frog, Litoria caerulea
(L. caerulea), belongs to the tree frog family Hylidae. Most
members of this tree frog family can produce multiple defen-
sive and regulatory chemical compounds in their skin secre-
tions to provide protective survival advantages in their
natural environment. Compared with the peptide discovery
research on other tree frogs, previous studies on the skin
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secretions of L. caerulea were not as productive in terms of
peptide quantities acquired and in the limited identiﬁcation
of peptides with a range of bioactive properties. The original
study investigating peptides derived from L. caerulea was
conducted in 1993 by Waugh et al. [9] who reported the dis-
covery of 25 peptides from the secretions of the parotoid
glands, including Caerulein 1, eighteen Caerins, and six Caer-
idins (Caeridins 1–6), the latter also being evidenced later in
four other Australian frog species, including, L. gilleni, L.
splendida, L. xanthomera, and L. chloris. In 1997, Steinborner
et al. [10] reported the discovery of Caeridin 7.1 from the
dorsal glandular skin extract of the brown tree frog, Litoria
ewingii. Interestingly, with the Caeruleins showing hypoten-
sive bioactivity and the Caerins antimicrobial activity, the
Caeridins, however, were not reported to display any struc-
tural and functional resemblance to the Caerulein and Caerin
peptides. These small Caeridin peptides (about 1000–
1500Da), comprising of 12–15 amino acid residues, share
the same sequence -Gly-Leu-Leu/Phe- at the N-terminal
ends and -Leu/Ile NH2 at the C-terminal ends. Each of this
Caeridins may be well ﬁtted into an α-helical wheel with
clearly delineated hydrophilic and hydrophobic zones [9].
The possession of dominant hydrophobic zones may suggest
appreciable hydrophobic moments of these Caeridins and
consequentially may bind more easily to the surface of bio-
logical membranes [11]. However, despite their distinct
structural features, none of the Caeridins was reported to
have any bioactive functions within these previous studies,
which might explain why there has been no research reported
on Caeridins over the last 20 years. Here, we report the isola-
tion and structural characterisation of Caeridin-1 and two
novel Caeridins from the skin secretion of L. caerulea, which
were obtained through an ecofriendly method described pre-
viously [12], using parallel transcriptomic and peptidomic
analyses, as well as through examining their biological activ-
ities using synthetic versions in a variety of bioassays.
2. Results
2.1. “Shotgun” Cloning of cDNAs Encoding Caeridins. Prepro-
caeridin cDNAs were consistently cloned from the skin
secretion cDNA library, and each encoded a single copy of
Caeridin, which were named Caeridin-1, S5-Caeridin-1,
and Caeridin-a1 shown in Figure 1. The putative signal pep-
tide sequences were localized to the acidic spacer peptide and
were highly identical in structure. The latter encoding
regions were ﬂanked at the N-terminus by classical propep-
tide convertase-processing sites involving a propeptide con-
vertase with -Lys-Arg- (-KR-) cleavage speciﬁcity, which
suggested that there were mutations in the structure. Align-
ments of the full-length nucleic acid sequences and the trans-
lated open-reading frame amino acid sequences are shown in
Figure 2 and highlight that preprocaeridins exhibit high
degrees of both nucleotide and peptide primary structural
similarities and conservation. Transcripts of Caeridin-1,
S5-Caeridin-1, and Caeridin-a1 were registered with and
deposited at http://www.ebi.ac.uk/ena/data/view/ perma-
nently under the accession numbers LT852758, LT852759,
and LT853865, respectively. Caeridin-1, S5-Caeridin-1, and
Caeridin-a1 were compared with other Caeridins isolated
from L. caeulea, and their amino acid sequences showed cer-
tain degrees of similarities suggested by the amino acid
alignment in Figure 3.
2.2. Fractionation and Primary Structural Identiﬁcation of
Caeridins. The computed molecular masses of the deduced
primary structures of Caeridin-1, S5-Caeridin-1, and
Caeridin-a1 located within the open-reading frames of
respective cloned cDNAs were used to detect each Caeridin
within reversed-phase HPLC fractions as shown in Figure 4,
which were subjected tomass spectrometric analysis. The pri-
mary structures of each Caeridin were conﬁrmed by tandem
mass spectrometric (MS/MS) fragmentation as shown in
Figure 5 and Table 1. The existence of C-terminal amidation
of each Caeridin was conﬁrmed with the appropriated posi-
tioned G residue playing as the amide donor.
2.3. Secondary Structural Identiﬁcation and Physicochemical
Property Analysis of Caeridins. The puriﬁed synthetic repli-
cates of Caeridins were subjected to secondary structural
identiﬁcation. From the CD spectra, these positive bands at
190 nm and double-negative bands at 208nm and 222nm
in the 10mM NH4Ac with 50% TFE solution indicated that
Caeridin-1, S5-Caeridin-1, and Caeridin-a1 adopted a typical
α-helical secondary structure in a membrane mimic environ-
ment (Figure 6). Multiple CD analysis methods were used
and processed by the K2D3 online portal to measure the α-
helicity of these Caeridins (Table 2) [13].
The newly discovered Caeridins together with the previ-
ously reported Caeridins were subjected to the analysis of
physicochemical properties by the Heliquest Analysis online
bioinformatic tool [14]. The hydrophobicity, hydrophobic
moment (amphipathicity), net charge, and charged residues
of these Caeridins were determined and are shown in Table 3.
2.4. Smooth Muscle Pharmacological Activities of Caeridins.
The puriﬁed synthetic replicates of Caeridins were subjected
to smooth muscle pharmacological activity tests. Caeridin-1
was found to induce contractions on rat bladder smooth
muscle, and S5-Caeridin-1 was found to have relaxation
eﬀects on rat ileum smooth muscle, at various concentra-
tions, as shown in Figure 7. The half eﬀective concentration
(EC50) of Caeridin-1 inducing rat bladder smooth muscle
contractions was 5.6 nM (5.6× 10−9M), and EC50 of S5-
Caeridin-1 causing rat ileum smooth muscle relaxations
was 9.5 nM (9.5× 10−9M). The maximum contraction eﬀect
of Caeridin-1 on bladder smooth muscle preparations was
0.3 g in tension change, and the maximum relaxant eﬀect of
S5-Caeridin-1 on ileum smooth muscle preparations was
0.2 g in tension change. Caeridin-a1 did not show any
smooth muscle activities.
2.5. Antimicrobial Activities of Caeridins. The puriﬁed syn-
thetic replicates of Caeridins were subjected to antimicrobial
activity tests, with melittin and bradykinin as positive and
negative controls, respectively. Melittin originally discovered
from the venom of the honeybee (Apis mellifera) has potent
antimicrobial activities. The inclusion of melittin as the pos-
itive peptide in the antimicrobial activity tests set a reference
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Figure 1: Continued.
3International Journal of Genomics
for the evaluation of the antimicrobial activity of the novel
peptides [15–17]. Bradykinin derived from the frog skin
extract of the European grass frog (Rana temporaria) is the
counterpart to mammalian bradykinins with no obvious
antimicrobial activities; thus, it is incorporated as the nega-
tive peptide in the antimicrobial activity tests [18–20].
Caeridin-a1 exhibited diﬀerent levels of antimicrobial
activities against the growth of the tested microorganisms
(Table 4) and demonstrated the most potent antimicrobial
activity against Staphylococcus aureus (S. aureus). It also
inhibited the growth of antibiotic-resistant bacteria,
methicillin-resistant S. aureus (MRSA), and Enterococcus
faecalis (E. faecalis), but slightly less potent than that against
S. aureus. It also had antimicrobial activities against the
Gram-negative bacterium, Escherichia coli (E. coli) and the
yeast, Candida albicans (C. albicans). Caeridin-1 and S5-
Caeridin-1 did not demonstrate any antimicrobial activities
on these tested microorganisms.
2.6. Membrane Permeability Studies. The novel antimicrobial
peptide Caeridin-a1, melittin, and bradykinin were tested in
the membrane permeability studies. Melittin is a canonical
membrane interactive peptide, so it was included as the pos-
itive peptide [15–17]. Bradykinin was referred to as the neg-
ative peptide for it is known to be inactive on membrane
interaction and permeabilisation [18–20].
2.6.1. Membrane Permeability Studies on S. aureus. The
peptide-induced permeabilisation of the cytoplasmic mem-
branes of S. aureus was detected using SYTOX Green, a
counterpart stain of nucleic acid and an indicator of dead
cells. The cell membrane of S. aureus remained intact after
being treated with the puriﬁed synthetic Caeridin-a1 (MIC)
for 2 h, but became massively compromised after being
treated with the puriﬁed synthetic Caeridin-a1 (MBC) for
the same period of time, as shown in Figure 8. This phenom-
ena suggested that Caeridin-a1 (MIC) failed to induce per-
meabilisation to the cytoplasmic membrane of S. aureus
within the 2 h treatment. After the 2 h treatment, the positive
peptide melittin produced approximately 50% membrane
permeability at MIC (1μM) and 100% membrane perme-
ability at MBC (2μM). The negative peptide bradykinin,
Caeridin-1, and S5-Caeridin-1 barely showed membrane-
permeabilising activity up to 512μM.
2.6.2. Membrane Permeability Tests on E. coli. The peptide-
induced membrane permeabilisation of E. coli was deter-
mined by the release of β-galactosidase activity into culture
medium MHB (2% lactose) using ONPG as the substrate.
As shown in Figure 9, the puriﬁed synthetic Caeridin-a1
(MIC and MBC) induced inner membrane permeabilisa-
tion within 30min given that the ONPG entered the cyto-
plasm and was degraded by β-galactosidase, generating
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Figure 1: Nucleotide sequences of full-length cDNA clones encoding open-reading frames of (a) preprocaeridin-1, (b) preproS5-caeridin-1,
and (c) preprocaerdin-a1 cloned from a Litoria caerulea (L. caerulea) skin secretion cDNA library. Putative signal peptide sequences are
double-underlined, mature Caeridin sequences are single-underlined, and stop codons are indicated by asterisks.
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o-nitrophenol that produced an absorbance at 420nm. The
Caeridin-a1-induced membrane permeabilisation of E. coli
was not as strong as the positive peptide melittin, evidenced
by the higher absorbance at 420nm, indicating an increased
production of o-nitrophenol by ONPG hydrolysis. Caeri-
din-1, S5-Caeridin-1, and the negative peptide bradykinin
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Figure 2: Alignments of (a) nucleotide sequences of cloned preprocaeridin cDNAs and (b) translated preprocaeridin open-reading frames
established MEGA6. The identical and conservative regions are highlighted in green and yellow, respectively. Putative signal peptide
sequences encoding regions and putative signal peptide sequences are double-underlined, and mature Caeridin sequences encoding
regions and mature Caeridins are single-underlined.
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Figure 3: Alignments of amino acid sequences of Caeridins identiﬁed from L. caerulea. The identical and conservative amino acids were
highlighted in green and orange, respectively.
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failed to induce membrane permeabilisation of E. coli, as no
absorbance increase was observed at 420 nm.
2.6.3. Membrane Permeability Study on Human Microvascular
Endothelial Cell Line, HMEC-1. The peptide-induced mem-
brane permeabilisation of normal human cells was evaluated
by the release of lactate dehydrogenase (LDH), a cytosolic
enzyme, from the damaged membrane of the human micro-
vascular endothelial cell line HMEC-1. After treatment with
Caeridin-1, S5-Caeridin-1, and negative peptide bradykinin
at concentrations of 10−7M to 10−4M, lower than 5% of
membrane lysis was resulted (Figures 10(a), 10(b), and
10(e)). In comparision, Caeridin-a1-induced membrane per-
meabilisation of HMEC-1 cells was indicated by about 50%
of LDH release at 100μM and approximately 10% LDH
release at 10μM (Figure 10(c)). The positive peptide melittin
showed membrane permeability in HMEC-1 cells at a con-
centration as low as 0.1μM, suggested by approximately
10% LDH release (Figure 10(d)). As the level of LDH released
into the medium is indicative of cytotoxicity, Caeridin-1, S5-
Caeridin-1, and negative peptide bradykinin showed weak
cytotoxicity to HMEC-1 cells at 100μM, while Caeridin-a1
and positive peptide melittin showed signiﬁcant cytotoxicity
at 100μM. However, at the lower tested concentrations, no
cytotoxicity was detected with Caeridins and negative pep-
tide bradykinin.
2.7. Haemolysis Induced by Caeridins. Haemolytic activities
of Caeridins, positive peptide melittin, and negative pep-
tide bradykinin were studied using horse erythrocytes as
shown in Figure 11. Melittin was incorporated as the positive
peptide due to its known haemolytic activities. The amphib-
ian bradykinin, the counterpart to mammalian Bradykinin,
has so little haemolytic activities that it was included in the
haemolysis test as the negative peptide [15–20]. The incorpo-
ration of melittin and bradykinin as positive and negative
peptide provided evidence on the evaluation of the haemoly-
tic activities of the novel peptides. Bradykinin, Caeridin-1,
and S5-Caeridin-1 exhibited weak haemolytic activities at
the tested concentrations, while Caeridin-a1 exhibited 18%
haemolysis at 32μM, and positive peptide Melittin showed
eminent haemolysis from 1μM.
3. Discussion
Peptides could oﬀer multiple beneﬁts over other drug treat-
ments, such as higher potency, higher selectivity, a broader
range of targets, potentially lower toxicity, lower accumula-
tion in tissues, more abundance in chemical and biological
diversity, discoverability at amino acid and nucleotide levels,
and relatively low cost in production [2]. Thus, the future of
many medicinal treatments could depend on the use of pep-
tides and peptide-based drugs [21]. Frog skin secretions have
been recognised as a valuable source of abundant bioactive
peptides which are generally categorised and grouped into
cytolytic peptides and pharmacologically active peptides
[6]. Given their bioactive potential, there are now global
eﬀorts to minimise the observed global decline in frog popu-
lations through frog protection and environmental conserva-
tion strategies, along with the development of improved
animal-friendly methods to conduct peptide discovery exper-
iments from frog skin secretions [22–24].
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Figure 5: Annotated tandemmass (MS/MS) fragmentation spectrum of (a) Caeridin-1, (b) S5-Caeridin-1, and (c) Caeridin-a1. The observed
b ions and y ions are labelled in blue and red, respectively.
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Within this study, we have successfully constructed a
cDNA library of the lyophilized skin secretion of the Austra-
lian White’s tree frog, L. caerulea. L. caerulea, a member of
the tree frog family Hylidae, was selected for analysis as it has
been understudied to date and has multiple skin-defensive
and regulatory compounds with signiﬁcant pharmaceutical
potentials that warrant further investigation [25, 26]. So
far, three major peptide families have been identiﬁed
from L. caerulea, namely, Caerins, Caeruleins, and Caeri-
dins [9]. Caerins were found similar in primary structures
with conserved -Gly-Leu- at the N-terminus, and they pos-
sess suﬃcient physiochemical characteristics to carry out
Table 1: Predicted singly and doubly charged b ions and y ions arising from MS/MS fragmentation of (a) Caeridin-1, (b) S5-Caeridin-1, and
(c) Caeridin-a1. Actual fragment ions observed following MS/MS fragmentation are indicated in bold and italic.
Number 1 b(1+) b(2+) Seq. y(1+) y(2+) Number 2
(a)
1 58.03 29.52 G 12
2 171.11 86.06 L 1083.68 542.34 11
3 284.20 142.60 L 970.59 485.80 10
4 399.27 200.12 D 857.39 429.26 9
5 456.25 228.63 G 742.48 371.74 8
6 569.33 285.17 L 685.46 343.23 7
7 682.33 341.71 L 572.38 286.69 6
8 739.30 370.22 G 459.21 230.15 5
9 840.58 420.74 T 402.27 201.64 4
10 953.41 477.29 L 301.22 151.12 3
11 1010.50 505.80 G 188.05 94.57 2
12 L-Amidated 131.12 66.06 1
(b)
1 58.03 29.52 G 12
2 171.11 86.06 L 1069.66 535.33 11
3 283.94 142.60 L 956.58 478.79 10
4 399.22 200.12 D 843.43 422.25 9
5 486.26 243.63 S 728.43 364.74 8
6 599.31 300.17 L 641.38 321.22 7
7 712.42 356.72 L 528.35 264.68 6
8 769.29 385.23 G 415.25 208.14 5
9 826.47 413.74 G 358.25 179.63 4
10 939.46 470.28 L 301.22 151.12 3
11 996.51 498.79 G 188.14 94.57 2
12 L-Amidated 131.12 66.06 1
(c)
1 58.03 29.52 G 15
2 171.11 86.06 L 1413.88 707.44 14
3 318.18 160.09 F 1300.79 650.90 13
4 433.21 217.61 D 1153.73 577.67 12
5 546.29 274.15 I 1038.70 519.86 11
6 645.36 323.68 V 925.62 463.31 10
7 702.38 352.19 G 826.46 413.78 9
8 830.48 415.7 K 769.53 385.27 8
9 943.48 472.3 L 641.38 321.22 7
10 1056.45 528.8 L 528.22 264.68 6
11 1113.41 557.3 G 415.07 208.14 5
12 1169.48 585.9 G 358.25 179.63 4
13 1283.51 642.2 L 301.22 151.12 3
14 1340.79 670.7 G 188.05 94.57 2
15 L-Amidated 131.12 66.06 1
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antimicrobial activities [27]. Caeruleins, similar to the mam-
malian cholecystokinin-8 (CCK-8) and hexagastrin, were
proven as powerful pharmacological peptides inducing gas-
trointestinal smooth muscle contractions and analgesic and
hormonal activities [28]. Caeridins, unfortunately, were
reported to have neither antimicrobial activities nor pharma-
cologically active activities [9]. From the constructed cDNA,
we have consistently cloned three diﬀerent preprocaeridin
cDNAs by means of a 3′-RACE strategy, using a degenerate
sense primer pool designed to a conserved nucleotide
sequence in the 5′ untranslated region of homologous Caerin
cDNA. These clones contained full-length open-reading
frames of preprocaeridins. The signal peptide primary struc-
tures and nucleic acid sequences are highly conserved and
some are identical, and the conserved trends extend to the
acidic prosegments, but not very obviously conserved when
it comes to mature peptide encoding regions, as shown in
Figure 2. All these mature peptides deduced from cloned skin
secretion cDNAs were found to have a C-terminal amidation
in the corresponding reversed-phase HPLC fractions by the
subsequent mass spectrometric analysis as shown in
Figures 5 and 6. These mature peptides were subsequently
compared with the protein database of the National Center
of Biotechnology Information (NCBI), and it was found that
one of these mature peptides was identical to Caeridin-1 with
unknown transcriptomic information [9], here also called
Caeridin-1. The peptide with two amino acids diﬀerent
from Caeridin-1 was called S5-Caeridin-1, and the ﬁnal
peptide with 80% identity to Caeridin-2 and Caeridin-3
was called Caeridin-a1.
The chemical synthetic replicates of Caeridin-1, S5-
Caeridin-1, and Caeridin-a1 were tested through various
bioassays. Antimicrobial activities of these Caeridins were
screened on standard bacteria and drug-resistant bacteria
given that peptides have previously shown potential to be
developed as conventional antibiotic alternatives to unravel
the global antimicrobial resistance. Smooth muscle is of great
signiﬁcance in physiological modulation; for example, the
smooth muscle in the uterus helps in parturition, the smooth
muscle in the bladder helps in uresis, the smooth muscle in
arteries determines blood ﬂow, and the smooth muscle in
the digestive tract modulate nutrients and wastes mobility.
Therefore, pharmacological activities of these Caeridins were
tested on diﬀerent rat smooth muscles.
Caeridin-1 and S5-Caeridin-1, deﬁcient of physiochemi-
cal properties, were found to have no eﬀects on membrane
interaction and disruption and thus failed to show antimicro-
bial activities [29]. However, Caeridin-1 was found to medi-
ate a contraction of rat urinary bladder smooth muscle with
EC50 = 5 6 nM and a maximum contraction of 0.3 g in ten-
sion change with no haemolytic eﬀects. S5-Caeridin-1 was
found to induce a relaxation of rat ileum smooth muscle with
EC50 = 9 5 nM and a maximum relaxation of 0.2 g in tension
change with no haemolysis. The discovery of Caeridin-1 and
S5-Caeridin-1 provided templates for developing urinary
system and digestive system regulatory drugs, but the mech-
anisms of action need further investigations.
Caeridin-a1 was recognised to be neutral in charge, with
a basic amino acid, -Lys-, and an acidic amino acid, -Asp-,
and adopted α-helical conformation in the membrane-
mimetic environment. Caeridin-a1 was found to be inhib-
itory against the growth of normal microorganisms, the
Wavelength (nm)
[휃
] (
de
g 
cm
2  d
m
ol
−1
)
190 200 210 220 230 240 250 260
0
1.5 × 105
1.0 × 105
5.0 × 104
−5.0 × 104
−1.0 × 105
−1.5 × 105
Caeridin-a1 + 10 mm NH4Ac
Caeridin-a1 + 50% TFE
Caeridin-1 + 10 mm NH4Ac
Caeridin-1 + 50% TFE
S5-Caeridin-1 + 10 mm NH4Ac
S5-Caeridin-1 + 50% TFE
Figure 6: CD spectra under diﬀerent conditions measured from 260 nm to 190 nm and plotted as mean residue ellipticity θ versus
wavelength.
Table 2: Secondary structures of Caeridin-1, S5-Caeridin-1, and
Caeridin-a1 deduced from CD spectra by K2D3 programme.
Peptide Method α β
Caeridin-1 K2D3 86.68% 0.02%
S5-Caeridin-1 K2D3 94.98% 0.01%
Caeridin-a1 K2D3 95.13% 0.02%
α = helices; β = strands.
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Table 3: Physicochemical properties of Caeridins determined by Heliquest.
Peptides Hydrophobicity Hydrophobic moment Net charge Charged residues
Caeridin-1 0.807 0.417 −1 ASP 1
S5-Caeridin-1 0.783 0.413 −1 ASP 1
Caeridin-a1 0.77 0.477 0 ASP 1, LYS 1
Caeridin-2 0.751 0.45 −1 ASP 1
Caeridin-3 0.735 0.489 −1 ASP 1
Caeridin-4 0.725 0.421 −1 ASP 1
Caeridin-5 0.841 0.369 0 none
Caeridin-6 0.878 0.377 0 none
Caeridin-7.1 0.757 0.615 −1 ASP 1
Rat Bladder
−11 −10 −9 −8 −7 −6
0.0
0.1
0.2
0.3
0.4
0.5
Log (concentration) M
C
on
tr
ac
tio
n 
(g
)
Caeridin-a1
S5-Caeridin-1
Caeridin-1
(a)
Re
la
xa
tio
n 
(g
)
−11 −10 −9 −8 −7 −6
Log (concentration) M
Caeridin-a1
S5-Caeridin-1
Caeridin-1
Rat Ileum
0.20
0.15
0.10
0.05
0.00
0.25
(b)
Figure 7: Dose-response curves of (a) synthetic Caeridins using rat urinary bladder smooth muscle preparations and (b) synthetic Caeridins
on rat ileum smooth muscle preparations. Each point represents the mean and standard error of mean (SEM) of 5 determinations.
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Gram-positive bacterium, S. aureus, the Gram-negative
bacterium, E. coli, and the yeast, C. albicans, as well as
against MRSA and β-lactam-resistant bacterium E. faecalis
which are hard to be controlled by conventional antibi-
otics and tend to cause more virulent infections. Antimi-
crobial susceptibility tests suggest that Caeridin-a1
showed better antimicrobial potency against the Gram-
positive bacteria, S. aureus, MRSA, and E. faecalis, with
MIC at 8μM, 16μM, and 32μM, respectively, but less
potent against the Gram-negative bacterium, E. coli, with
MIC at 32μM. As the membrane disruption is recognised
as one of the mechanisms of antimicrobial actions of anti-
microbial peptides, membrane permeability tests were
performed on the standard Gram-positive bacterium (S.
aureus) and Gram-negative bacterium (E. coli). The
Caeridin-a1-induced membrane permeabilisation of S.
aureus was monitored only at its MBC (16μM), indicating
that Caeridin-a1 at its MIC = 8 μM was not able to per-
meabilise the cytoplasmic membrane within 2 h. However,
Caeridin-a1 induced membrane permeabilisation of E. coli
within 30min at both its MIC (32μM) and MBC (64μM)
against E. coli. The signiﬁcant membrane-disruptive eﬀect
of Caeridin-a1 was also observed in HMEC-1 cells at
100μM and was weakened with the decrease of the pep-
tide concentration. These results suggest that the swift
membrane permeability depends on the administrated
concentration of Caeridin-a1. Caeridin-a1 at its higher
concentrations could rapidly and unspeciﬁcally interact
and disrupt the cytoplasmic membrane leading to cell
lysis, but Caeridin-a1 at its lower concentrations may per-
form antimicrobial activities by other mechanisms or may
need longer time to induce membrane permeabilisation.
Caeridin-a1 was also found to induce haemolysis at higher
concentrations, whereby 18% haemolysis was detected at
32μM, which consequently decreases its potential thera-
peutic value. However, the size of Caeridin-a1 is relatively
small with only 15 amino acid residues, and therefore,
Caeridin-a1 could be used as a template for developing
smaller antimicrobial peptides after rational structural
modiﬁcation, which may be of interest to the pharmaceu-
tical industry due to reduced cost of development and eas-
ier manufacturing processes.
Table 4: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of Caeridins, melittin, and bradykinin
against diﬀerent tested microorganisms.
Peptides
MIC/MBC (μM) MIC/MFC (μM)
S. aureus NCTC10788 MRSA NCTC12493 E. faecalis NCTC12697 E. coli NCTC10418 C. albicans NCYC1467
Caeridin-a1 8/16 16/32 32/64 32/64 32/64
S5-Caeridin-1 >512/>512 >512/>512 >512/>512 >512/>512 >512/>512
Caeridin-1 >512/>512 >512/>512 >512/>512 >512/>512 >512/>512
Melittin 1/2 2/4 2/4 4/8 1/8
Bradykinin >512/>512 >512/>512 >512/>512 >512/>512 >512/>512
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Figure 8: Membrane permeabilisation of S. aureus treated with melittin (MIC = 1μM and MBC = 2 μM), Caeridin-a1 (MIC = 8μM and
MBC = 16μM), Caeridin-1 (512 μM), S5-Caeridin-1 (512 μM), bradykinin (512 μM), and 70% isopropanol for 2 h. The degree of
membrane permeability was calculated in comparison with the maximum membrane permeabilisation control (70% isopropanol-treated).
The error bars represent SEM of three independent experiments and each experiment with ﬁve replicates.
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Although the Caeridins discovered in this study share a
similar amino acid composition and structural elements with
each other and with the Caeridins reported previously, the
bioactivities they exhibited are diﬀerent. Only Caeridin-a1
was found to demonstrate potent antimicrobial and hae-
molytic eﬀects, but Caeridin-1, S5-Caeridin-1, and other
reported Caeridins were not. This could be explained by the
variation in the membrane-disruptive action of peptides.
The Gram-positive bacterial cell walls contain anionic tei-
choic acids and lipoteichoic acids. The anionic lipopolysac-
charides are widely distributed in the outer leaﬂet of the
outer membrane of Gram-negative bacteria. The negatively
charged glycosaminoglycans and gangliosides are composed
in mammalian cells exterior to the cytoplasmic membrane.
Firstly, amphipathic peptides with positively charged resi-
dues are attracted to the vicinity of the cell surface by electro-
static actions. Secondly, peptides attach to the cell membrane
via electrostatic and hydrophobic interactions. Then they
undergo conformational transition to bind with the mem-
brane and form transmembrane pores/channels or translo-
cate phospholipid bilayers, thus destroying the membrane
integrity. Because of the abundance of the acidic phospho-
lipids, such as cardiolipin and phosphatidylglycerol, and the
absence of sterol, in the cytoplasmic membrane of bacteria,
amphipathic peptides with cationic residues are able to attach
to the bacterial membrane by both electrostatic interaction
and hydrophobic interaction. However, the mammalian cell
membranes only have acidic phospholipids at the inner facet
of the phospholipid bilayers, suggesting that peptides are
more able to interact with the mammalian cell membrane
by hydrophobic interaction. In addition to phospholipids,
the numerous sterols embedded in the bilayers impede the
peptide from better binding with the membrane and trigger-
ing further membrane disruption, which is the same on red
blood cells. The cationic residue, -Lys-, in the amino acid
composition of Caeridin-a1 may facilitate the peptide being
better attracted to the cell surface and interacting with the
cell membrane by electrostatic eﬀects, though the net charge
of Caeridin-a1 was 0 due to the presence of the anionic res-
idue, -Asp-. In addition to electrostatic interaction, the high
amphipathicity and hydrophobicity of Caeridin-a1 may also
promote the peptide to bind to the cell membrane by hydro-
phobic interaction. Then, Caeridin-a1 may conform to an α-
helical structure to bind with the membrane and form trans-
membrane pores, thus destroying the membrane. Therefore,
Caeridin-a1 was able to disrupt the non-sterol-protected
bacterial cell membrane at lower concentrations, and ste-
rol/cholesterol-protected mammalian cell membrane and
red blood cell membrane at higher concentrations, showing
antimicrobial eﬀects on the tested microorganisms, cytotoxic
eﬀects on HMEC-1 cells, and haemolytic eﬀects on the horse
erythrocytes. Regarding the other Caeridins, as shown in
Table 3, the net charge of Caeridin-1, S5-Caeridin-1, Caeri-
din-2-4, and Caeridin-7.1 is −1 due to the presence of an
acidic residue, -Asp-, and the net charge of Caeridin-5 and
Caeridin-6 is zero because of the lack of charged residues.
Therefore, these Caeridins are expected to fail to undergo
electrostatic attraction and interaction with the membrane.
They showed no membrane disruption in the tested micro-
organisms, mammalian cells, and horse red blood cells.
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Figure 9: Membrane permeabilisation of E. coli treated with Caeridin-a1, Caeridin-1, S5-Caeridin-1, melittin, and bradykinin. The hydrolysis
of ONPG generated by the release of cytoplasmic β-galactosidase of E. coli after treatment at MIC andMBC of Caeridin-a1, MIC andMBC of
melittin, and maximum tested concentration of Caeridin-1, S5-Caeridin-1, and bradykinin was measured spectroscopically at 420 nm UV for
30min. Each point represents mean absorbance and SEM of three independent experiments and each experiment with ﬁve replicates.
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Although no antimicrobial eﬀects were detected, Caeridin-1
and S5-Caeridin-1 were presumed to be mediated by the G
protein-coupled receptors to induce contraction and relaxa-
tion of smooth muscle preparations with no haemolysis and
cytotoxicity. However, Caeridin-a1 with strong membrane
disruptive activity would also cause damage to smooth mus-
cle cell membrane; thus, no smooth muscle activities were
found with Caeridin-a1.
The discovery of Caeridin-1, S5-Caeridin-1, and
Caeridin-a1 reinforced the multiple bioactivities of the Caer-
idin peptide family. Although they are very similar with other
reported Caeridins, certain amino acid mutations were iden-
tiﬁed. It is these small mutations in amino acid sequences and
compositions that aﬀect physicochemical characteristics and
functioning structures and lead to big diﬀerences in bioactiv-
ities. Therefore, optimal amino acid sequence selections from
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Figure 10: Membrane permeabilisation of humanmicrovascular endothelial cell line, HMEC-1, reﬂected by the level of LDH released into the
medium, after being treated by (a) Caeridin-1, (b) S5-Caeridin-1, (c) Caeridin-a1, (d) positive peptide melittin, and (e) negative peptide
Bradykinin. The level of LDH release was calculated in comparison with the maximum LDH release control group (lysis buﬀer-treated)).
∗∗∗∗p < 0 0001 represents a signiﬁcant change in the level of LDH release, compared with the maximum LDH release control group (lysis
buﬀer-treated), using one-way analysis of variance followed by Dunnett’s multiple comparisons tests. The error bar represents SEM of
three independent experiment determinations and each experiment with triplicates.
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frog skin secretions lay a foundation for peptide discovery
and development.
4. Materials and Methods
4.1. Collection of Frog Skin Secretions. The adult Australian
frogs (n = 4), L. caerulea, were captive bred and kept for three
months before the collection of their skin secretions. Their
defensive skin secretions were collected from their dorsal
skin by mild transdermal electrical stimulation according to
the technique reported by Tyler et al. [30], then lyophilised
and stored at −20°C prior to analysis. Sampling of skin secre-
tion was performed by Mei Zhou under UK Animal (Scien-
tiﬁc Procedures) Act 1986, project license PPL 2800, issued
by the Department of Health, Social Services and Public
Safety, Northern Ireland. Procedures had been vetted by the
IACUC of Queen’s University Belfast and approved on 19
February 2016.
4.2. “Shotgun” Cloning of Novel Caeridin Precursor-Encoding
cDNAs from the Skin Secretion-Derived cDNA Library of L.
caerulea. The cDNA library of L. caerulea was established
through the reverse transcription of the mRNA. The mRNA
was extracted from the lyophilised skin secretion by using
Dynabeads® mRNA DIRECT™ Kit (Life Technologies, Oslo,
Norway). The extracted mRNA was reverse transcribed to
synthesise the ﬁrst-strand cDNA by following the instruc-
tions described by the BD SMART™ RACE cDNA Ampliﬁ-
cation Kit (Clontech, Palo Alto, CA, USA) to establish the
cDNA library. The cDNA library was subjected to 3′-RACE
(rapid ampliﬁcation of cDNA ends) procedures to obtain
full-length preprocaeridin nucleic acid sequence data with
a SMART-RACE Kit (Clontech, Palo Alto, CA, USA)
according to the manufacturer, which involved a NUP
primer supplied with the kit and a degenerate sense primer
pool (S1: 5′-GVCCTTGTAAAGACCAAVCATGGCTT-3′)
designed to a segment of the 5′-untranslated region of Caerin
cDNAs cloned from the skin secretion of L. caerulea (EMBL
accessionNumber AY218778-82). This approach was applied
as the segment of the 5′-untranslated region employed was
found to be highly conserved among the homologous peptide
cDNAs [31]. An additional advantage of this strategy was that
the entire open-reading frame of these transcripts could be
deduced through a single 3′-RACE procedure. This PCR
cycling procedure was carried out as follows: initial denatur-
ation step: 60 s at 94°C; 40 cycles of ampliﬁcation: denaturing
for 30 s at 94°C; primer annealing for 30 s at 61°C; and strand
extension for 180 s at 72°C. RACE-PCR products were ana-
lysed by DNA agarose gel electrophoresis, puriﬁed, and
cloned in a pGEM®-T Easy vector system (Promega Corpo-
ration, Southampton, UK), and the selected samples were
sequenced by an ABI 3730 DNA automated analyser
(Applied Biosystems, Foster City, CA, USA). The nucleic
acid sequences were translated into amino acid sequences
by the ExPASy Translate Tool online portal. The deduced
preprocaeridins were analysed using the Blast Alignment
Search Tool (BLAST) of the National Centre for Biotechnol-
ogy Information (NCBI) by comparing to peptides with
known amino acid sequences in the protein database.
Alignments of similar regions were established by MEGA
6. The nucleotide sequences of the cDNA encoding the
novel Caeridins were registered with the European Nucleo-
tide Archive (ENA) browser at http://www.ebi.ac.uk/embl/
genomes/submission/.
4.3. Chromatographic Isolation and Primary Structural
Characterisation of Novel cDNA-Deduced Caeridins from
the Skin Secretion of L. caerulea. The lyophilised skin
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Figure 11: Haemolytic activities of synthetic Caeridin-1, S5-Caeridin-1, Caeridin-a1, melittin, and bradykinin. The level of haemolysis tested
on horse red blood cells was calculated in comparison with the maximum haemolysis control (1% Triton X-100-treated). The error bar
represents SEM of three independent experiment determinations and each experiment with ﬁve replicates.
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secretion of L. caerulea dissolved in solution A (99.95%H2O,
0.05% triﬂuoroacetic acid (TFA) was fractionated by
reversed-phase HPLC using a Waters Binary pump HPLC
system (Waters, Milford, MA, USA) ﬁtted with an analytical
column (Jupiter, C5, 300Å, 5μm, 250mm× 4.6mm, Phe-
nomenex, Macclesﬁeld, Cheshire, UK) and eluted with a lin-
ear gradient formed from 100% solution A (99.95% H2O,
0.05% TFA) to 100% solution B (80.00% acetonitrile,
19.95% H2O, 0.05% TFA) in 240min at a ﬂow rate of
1000μl/min. Fractions were collected at each minute, and
the eﬄuent was continuously detected at λ = 214 nm. The
dead volume between column and fraction collector was
minimal (20μl).
The molecular masses of peptides in each fraction were
analysed by matrix-assisted laser desorption/ionisation
time-of-ﬂight mass spectrometry (MALDI-TOF MS) on a
linear time-of-ﬂight Voyager DE mass spectrometer (Voy-
ager DE, Perspective Biosystems, Foster City, CA, USA) in
a positive detection mode using α-cyano-4-hydroxycinnamic
acid matrix to construct a mass spectral library of the L. caer-
ulea skin secretion peptide. The instrument was calibrated in
the range of 1–4 kDa, and the accuracy of mass determina-
tions was ±0.1%. The computed molecular masses of pre-
dicted mature Caeridins deduced from encoded cDNA
were used to interrogate the mass spectral library to identify
the putative Caeridins. The skin secretion fractions contain-
ing the putative Caeridins diluted in solution A (99.90% H2
O, 0.10% formic acid) were pumped directly onto an analyt-
ical HPLC column (Jupiter, C18, 300Å, 5μm, 150mm×
4.6mm, Phenomenex, Macclesﬁeld, Cheshire, UK) con-
nected to an LCQ Fleet ESI ion-trap mass spectrometer
(Thermo Fisher, San Jose, CA, USA) and eluted from 100%
solution A (99.90% H2O, 0.10% formic acid) to 100% solu-
tion B (19.90% H2O, 80.00% acetonitrile, and 0.10% formic
acid) in 135min at a ﬂow rate of 20μl/min. Mass analysis
was performed in a positive ion mode with acquired spectra
in the range of 500–2000m/zwith>50%relative intensity dur-
ing HPLC-MS. Parameters for electrospray ionisation ion-
trap mass spectrometry (ESI/MS) were spray voltage
+4.5 kV, drying gas temperature 320°C, drying gas ﬂow
200μl/min, and maximum accumulation time (ion trap)
350ms. The ﬁrst mass analysis was performed in full-scan
mode, then peptide ions with >50% relative intensity were
selected for fragmentation by collision-induced dissociation
(CID), to generate b and y ions detected in a secondmass anal-
ysis. The instrument was controlled by Xcalibur software
(Thermo Fisher, San Jose, CA, USA), and data analysis was
performed using Proteome Discoverer 1.0 (Thermo Fisher,
San Jose, CA, USA). Sequest™ algorithm was employed to
compare the acquired fragment ion proﬁles with the theoreti-
cal fragment ions generated from a FASTA database speciﬁc
for this species built by “shotgun” cloning (as described above)
to conﬁrm the amino acid sequences of individual Caeridins.
4.4. Solid-Phase Peptide Synthesis. The novel Caeridins,
positive peptide Melittin, and negative peptide Bradykinin
were synthesised by solid-phase Fmoc chemistry using a
Tribute automated solid phase peptide synthesiser 4 (Protein
Technologies, Tucson, AZ, USA). After cleavage from resin
and deprotection, each crude peptide was obtained. The
amino acid sequences of these peptides are summarised in
Table 5. The authenticity of the synthetic peptides was estab-
lished by HPLC puriﬁcation and conﬁrmed by MALDI-TOF
(Voyager DE, Perspective Biosystems, Foster City, CA, USA)
and an LCQ Fleet electrospray ion-trap mass spectrometer
(Thermo Fisher Scientiﬁc, San Francisco, CA, USA).
4.5. Secondary Structural Determination by Circular
Dichroism (CD). CD spectra were obtained at 20°C using a
1mm high-precision quartz cell (Hellma Analytics, Essex,
UK) with a JASCO J-815 CD spectrometer (Jasco, Essex,
UK). The measurement range was from 260 nm to 190nm
at a scanning speed of 200nm/min. The bandwidth was
1 nm, and the data pitch was 0.5 nm. Caeridins were,
respectively, dissolved in 10mM NH4Ac or 10mM NH4A
c with 50% TFE to reach a ﬁnal concentration of 100μM.
The CD spectra were analysed by a K2D3 online portal pro-
gramme [13].
4.6. Rat Smooth Muscle Tests. Female Wistar rats (250–300 g)
were euthanized by CO2 asphyxiation followed by cervical
dislocation under appropriate Home Oﬃce (UK) animal
licenses. Full urinary bladder and ileum were carefully
removed from the abdomen, then placed in cold Kreb’s solu-
tion (118mMNaCl, 4.7mM KCl, 25mMNaHCO3, 1.15mM
NaH2PO4, 2.5mM CaCl2, 1.1mM MgCl2, and 5.6mM glu-
cose), equilibrated with a carbogen mixture (95% O2, 5%
CO2) [32]. The prepared smooth muscles linked with trans-
ducers were placed in 2ml capacity organ baths with Kreb’s
solution ﬂowing through at 2ml/min and maintained at
37°C with constant bubbling of carbogen gas mixture (95%
O2, 5% O2) and equilibrated for 1 h prior to analysis. Then
the viability of these smooth muscle preparations was tested
by 60mM KCl. Caeridins were tested at sequential molar
concentrations in the range from 10−6M to 10−11M. Dose-
response curves were depicted for each Caeridin on individ-
ual smooth muscle preparations (n = 5). Changes in tension
of the smooth muscle preparations were detected by pressure
transducers connected to a PowerLab System (ADInstru-
ments Pty Ltd.). Data were recorded and calculated to obtain
the means of responses and standard error of means (SEM).
The dose-response curve of each Caeridin was established
using best-ﬁt algorithms through the data analysis package
provided by GraphPad Prism (Version 6.0; GraphPad Soft-
ware Inc., San Diego, CA, USA), and the comparative EC50
value for each peptide was depicted.
4.7. Antimicrobial Tests. The antimicrobial activities were
tested by the broth microdilution method and evaluated
by the determination of MIC values against diﬀerent
tested microorganisms, the Gram-positive bacteria, S. aureus
(NCTC 10788), E. faecalis (NCTC12697), and MRSA
(NCTC 12493); the Gram-negative bacterium, E. coli (NCTC
10418); and the yeast, C. albicans (NCYC 1467). The micro-
organisms were cultured to their log phase in MHB and
diluted to 5× 105CFU/ml then subsequently treated with
peptide solutions of gradient concentrations. After incuba-
tion at 37°C overnight, the growth of microorganisms was
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detected at a wavelength of 550nm using a Synergy HT plate
reader (Biolise BioTek ELx808, Winooski, VT, USA). The
MICs were determined as the lowest concentration of peptide
where growth was detectable.
4.8. Cell Membrane-Permeable Tests. The cell membrane per-
meability of S. aureus was tested with SYTOX Green Nucleic
Acid Stain (Life Technologies, Carlsbad, CA, USA). The log-
phase S. aureus was pelleted and suspended in 5% TSB in
0.85% NaCl solution to achieve 1× 108CFU/ml cells which
was then treated with peptide solutions at 37°C for 2 h. The
maximum membrane-compromised S. aureus was produced
by 70% isopropanol treatment. Subsequently, cells were
mixed with 5μM SYTOX Green stain and incubated in the
dark for 10min. The ﬂuorescence was measured in a 37°C
Synergy HT plate reader (Biolise BioTek ELx808, Winooski,
VT, USA) at excitation and emission wavelengths of
480nm and 528 nm, respectively. The membrane permeabil-
ity was calculated as
Membrane permeability % = F − F0
F1 − F0
× 100%, 1
where F represents the processed ﬂuorescence intensity with
peptide treatments, F0 represents the processed ﬂuorescence
intensity of untreated S. aureus, and F1 represents the proc-
essed ﬂuorescence intensity in the maximum membrane-
compromised S. aureus (70% isopropanol-treated). The ﬂuo-
rescence intensities of background were subtracted prior to
calculation.
The membrane permeabilsation of E.coli was determined
by measuring the release of β-galactosidase activity from E.
coli into the culture medium with ONPG as the substrate.
The log-phase E. coli was grown in MHBmedium containing
2% lactose at 37°C, and the cells were pelleted. The cell pellets
were suspended in 10mM PBS (pH7.4) containing 1.5mM
ONPG and diluted to 1× 108CFU/ml. Aliquots of cells were
incubated with diﬀerent concentrations of peptides at 37°C.
Permeabilisation was measured at 420 nm every 2min from
0 to 30min, which reﬂects ONPG inﬂux into the cells work-
ing as an indicator of the permeability of the tested peptides.
The membrane permeabilisation of the humanmicrovas-
cular endothelial cell line, HMEC-1, was evaluated using the
Pierce LDHCytotoxicity Assay Kit (Thermo Fisher Scientiﬁc,
San Francisco, CA, USA). HMEC-1 cells were cultured in
MCDB-131 medium (Life Technology, Paisley, UK) with
10% FBS, 10 ng/ml epidermal growth factor (EGF) (Life
Technology, Paisley, UK), 10mM L-glutamine (Life Tech-
nology, Paisley, UK), and 1% penicillin-streptomycin
(Sigma-Aldrich, St. Louise, MO, USA), at 37°C under 5%
CO2. Cells were seeded in a 96-well plate at 5000 cells per well
and cultured overnight to 80% conﬂuency. Then, the cells
were treated with diﬀerent peptide solutions of gradient con-
centrations from 10−7M to 10−4M for 24 h at 37°C, 5% CO2,
and H2O-treated cells were made as the spontaneous LDH
release control. Lysis buﬀer was added to cells and incubated
for 45min at 37°C, 5% CO2, to produce the lysis buﬀer-
treated cells which were referred to as maximum LDH release
control. Then 50μl of each sample supernatant was trans-
ferred to a 96-well ﬂat-bottom plate in triplicate wells, to
which 50μl of reaction mixture was added, incubated, and
protected from light at room temperature for 30min. After
addition of 50μl Stop Solution to each sample well and
removal of bubbles present in sample wells, the absorbance
at 490nm and 680nm was measured. The absorbance values
at 680nm were subtracted from the absorbance values at
490 nm before calculation of the level of LDH release (cyto-
toxicity). The level of LDH release was calculated as
LDH release % = L − L0
L1 − L0
× 100%, 2
where L refers to sample-treated LDH activity, L0 to sponta-
neous (H2O-treated) LDH activity, and L1 to maximum (lysis
buﬀer-treated) LDH activity.
Data analysis was performed using one-way analysis of
variance followed by Dunnett’s multiple comparison tests
with maximum LDH release control in GraphPad Prism
(Version 6.0; GraphPad Software Inc., San Diego, CA, USA).
4.9. Haemolytic Tests. The haemolysis of Caeridins was tested
on prepared defrinated horse red blood cells (TCS Biosci-
ences Ltd., Buckingham, UK) by incubating equal volumes
of peptide solutions with erythrocyte suspensions at 37°C
for 2H.Maximum haemolysis control was included by incu-
bating equal volumes of 1% Triton X-100 (Sigma-Aldrich, St.
Louis, MO, USA) with erythrocyte suspensions. Lysis of
erythrocytes was detected by the measurement of superna-
tant absorbance at a wavelength of 550nm using a Synergy
HT plate reader (Biolise BioTek ELx808, Winooski, VT,
USA). The level of haemolysis was as calculated as
Haemolysis % = A − A0
A1 − A0
× 100%, 3
where A represents the absorbance with peptide treatments,
A0 represents the average absorbance in untreated erythro-
cytes, and A1 represents the average absorbance in the max-
imum haemolysis control (1% Triton X-100-treated).
5. Conclusions
The discovery of Caeridin-1, S5-Caeridin-1, and Caeridin-a1
not only contributed templates for drug design but also
provided evidence that peptides from frog skin secretions
possess bioactive properties and uphold expectations that
Table 5: The amino acid compositions of novel Caeridins, positive
peptide melittin, and negative peptide bradykinin.
Peptide Amino acid sequence
Caeridin-1 H2N-GLLDGLLGTLGL-CONH2
S5-Caeridin-1 N2H-GLLDSLLGGLGL-CONH2
Caeridin-a1 H2N-GLFDIVGKLLGGLGL-CONH2
Melittin
H2N-GIGAVLKVLTTGLPALISWIKRKRQQ-
CONH2 [15–17]
Bradykinin H2N-RPPGFSPFR-COOH [18–20]
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peptides derived from natural resources may contribute to
the clinical development of novel therapeutics.
Abbreviations
HPLC: High-performance liquid
chromatography
MIC: Minimum inhibitory concentration
MBC: Minimum bactericidal concentration
CID: Collision-induced dissociation
MALDI-TOF MS: Matrix-assisted laser desorption/ionisa-
tion time-of-ﬂight mass spectrometry
ESI/MS: Electrospray ionisation ion-trap mass
spectrometry.
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